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musculoskeletal injuries at a cost of $9.8 
billion annually in the USA.[5] With an 
ageing population, >1 million fractures 
are expected to occur annually by 2050.[5] 
Thus, there is an urgent need to develop 
new bone repair therapies that are safe, 
cost-effective, and efficacious.
Currently, therapeutic approaches 
for the treatment of nonunion fractures 
include growth factor (GF)-based treat-
ments,[6,7] stem cell therapies,[7] and mag-
netic field treatments.[7,8] GFs, in particular 
bone morphogenetic proteins (BMPs), are 
commonly used in fracture treatments. 
However, they are not without limitations, 
including partial efficacy[9]; uncontrolled 
and nonlocalized delivery, which can pro-
duce potentially harmful, nonspecific, sys-
temic side effects[10–12]; and high cost due 
to the large doses of GFs used.[9,13]
BMP-2 has been used for over a decade 
in bone regenerative therapies, loaded into collagen sponges at 
high concentrations (1.5 mg mL−1).[14] Despite the US Food and 
Drug Administration (FDA) releasing a notification of the life-
threatening complications associated with the therapeutic use of 
high-dose BMP-2 for bone repair, including ectopic bone forma-
tion, neurological problems, and high risk of cancer, the use of GF 
therapies continues.[15] Nevertheless, new advanced technologies 
are being developed to replace existing GF-based treatments by 
exploiting the bioactive properties of materials.[16–22] Still, the 
translation of materials-based platforms from in vitro and in vivo 
lab testing through to clinical applications remains limited due to 
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1. Introduction
Active lifestyles in the young, obesity, diabetes, and osteopo-
rosis in the elderly are driving an increase in the occurrence 
of traumatic injury. In 2010, >250 000 people in the USA 
over the age of 65 were hospitalized for hip fractures,[1] with 
an increasing number of patients experiencing nonhealing 
(known as nonunion) fractures.[2] Rates of nonunions from 2 to 
5% have been recently suggested,[3,4] with important variations 
with type of fracture, age, gender, and risk factors. Nonunion 
fractures account for the most inpatient hospital days of all 
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overengineering, use of novel chemistry unlikely to gain regula-
tory approval, and/or complex grafting of biologicals.
Structural scaffolds based on FDA-approved materials can 
potentially be used in conjunction with bioactive polymer 
coatings. One such bioactive polymer is poly(ethyl acrylate) 
(PEA).[17] We have previously shown that while fibronectin 
(FN) typically adsorbs onto polymers in globular conforma-
tion, PEA promotes the spontaneous organization of FN into 
physiological-like networks. When assembled, these networks 
present both integrin-binding (III9–10) and GF-binding (III12–14) 
regions to cells.[17,23] Importantly, the GF-binding region can 
stably present GFs, such as BMP-2, at ultralow doses.[17] How-
ever, the application of bioactive polymer coatings, such as PEA, 
to 3D scaffolds and their clinical translation have been hindered 
by several limitations. First, the current predominant technique 
for coating a surface with PEA is spin coating,[17,24] which is 
difficult to achieve on a 3D scaffold. Second, PEA is nonbiode-
gradable. One solution to this problem would be to coat a bio-
degradable polymeric scaffold with a layer of PEA that is thin 
enough (<10s of nm) for the body to metabolize after the scaf-
fold has degraded.[25,26] Standard polymer coating techniques 
such as spin coating typically yield a PEA coating with a thick-
ness of ≈1 µm on a flat surface. This is too thick for clinical pur-
poses, even if spin coating was to be successfully implemented 
on a 3D scaffold. Spin coating also requires PEA to be dissolved 
in an organic solvent and thus traces of harmful solvents can 
remain. We therefore sought to develop a solvent-free coating 
method[24] with nanoscale coating depth that could be applied to 
a variety of 3D applications, such as scaffolds and grafts.
To achieve this, we present a simple, robust, and translational 
approach to promoting bone regeneration in nonunion bone 
defects. We report the development of a plasma–polymerization 
strategy for coating 3D scaffolds with thin layers of PEA. We 
show that this highly facile method can be used to coat 2D 
surfaces and complex 3D scaffolds, including 3D-printed scaf-
folds and microparticles, and that this coating can assemble FN 
in the form of biomimetic networks. We investigate whether 
these FN networks support synergistic interactions between inte-
grins and BMP-2 receptors that promote osteogenesis in vitro. 
Importantly, this nanoscale coating can be applied to 3D biode-
gradable materials and we investigate their use as an implant to 
advance bone healing in a mouse model of a critical-sized, non-
healing bone defect. We also report the first veterinary application 
of this technology to treat a 2-year-old Münsterländer dog with a 
nonhealing and infected fracture of the humerus. We treat this 
nonunion using PEA-coated decellularized bone chips seeking to 
promote rapid and robust healing of this bone defect and pre-
vent limb amputation. Together, we introduce a next-generation 
GF-based technology for effective bone repair in vivo that is likely 
safer in a clinical setting given the ultralow dose of BMP-2 used.
2. Results
2.1. Plasma-Polymerized PEA Coatings Promote FN Assembly 
and Effective BMP-2 Presentation
The plasma-based polymerization of ethyl acrylate into plasma-
polymerized PEA (pPEA) coatings is illustrated in Figure 1a. 
We used spin-coated PEA (a nontranslatable approach, as 
explained above), denoted as SC-PEA, as a positive control. 
When FN is coated on SC-PEA (open FN chain, illustrated in 
Figure 1b), BMP-2 binding, crosstalk with integrins, and oste-
ogenesis are promoted, as previously demonstrated.[17] The 
chemistry of pPEA was confirmed using X-ray photoelectron 
spectroscopy (XPS). The spectrum of pPEA shows a promi-
nent disappearance of the CO and COC moieties at 286.6 
and 533.5 eV, respectively, which differs from that of SC-PEA 
(Figure 1c,d).[27] It is known that plasma polymerization leads 
to partial loss of functional groups and crosslinking.[24] By fine-
tuning the parameters of the plasma system, such as chamber 
pressure, power, and polymerization time, we were able to coat 
pPEA onto glass at a rate of as low as 10 nm min−1 (Figure S1a, 
Supporting Information). The thickness of the deposited pPEA 
coatings (≈300 nm) guarantees that the XPS spectra are due 
to pPEA and not to the underlying substrate, as the sensitivity 
of XPS is ≈10 nm.[24] The stability of the films was confirmed 
by monitoring the water contact angle (WCA) after deposi-
tion and up to 14 d. Figure S1b in the Supporting Informa-
tion shows that WCAs remain unchanged at different time 
points after deposition (Figure S1b, Supporting Information). 
We measured the strength of interaction between pPEA coat-
ings and the underlying substrates using a normalized pull-off 
test that resulted in an adhesion strength of 7.14 ± 0.35 MPa 
(Figure S1c, Supporting Information). Changes in plasma 
settings resulted in coatings of different thicknesses but with 
similar XPS spectra, indicating that the properties of the pPEA 
deposited at different conditions were comparable (Figure S2, 
Supporting Information).
Atomic force microscopy (AFM) was performed to visualize 
the organization of FN on both SC-PEA and pPEA (Figure 1e,f). 
Poly(methyl acrylate) (PMA), which has one fewer carbon in its 
side chain, is a good control for PEA as it results in FN adsorp-
tion in globular conformation.[28–30] (Data on interactions with 
PMA are presented in Figure S3a,b in the Supporting Informa-
tion.) FN assembly into nanonetworks on SC-PEA (Figure 1e) 
has been well characterized previously.[28,29] It occurs when FN 
is adsorbed onto SC-PEA at a sufficiently high concentration 
(>10 µg mL−1) so that when FN unfolds, it can contact neigh-
bouring FN molecules. This allows nanonetworks to assemble 
via interactions among FN matrix-binding regions. AFM 
showed that pPEA coatings do indeed induce this FN assembly 
but with denser, thicker morphology compared with those 
formed on SC-PEA (Figure 1f and Figure S3c, Supporting 
Information), although the measured surface densities of FN 
adsorbed on pPEA and SC-PEA were similar (Figure 1g and 
Figure S3d, Supporting Information). Note that spin-coated 
PMA (Figure S3e, Supporting Information) did not induce 
fibrillogenesis (Figure S3a,b, Supporting Information).
To assess the activity of FN on pPEA, we quantified the avail-
ability of the integrin-binding and GF-binding regions using 
enzyme-linked immunosorbent assay (ELISA) with monoclonal 
antibodies against the respective regions (Figure 1h). We looked 
at the FN(III9–10) domain, which includes the RGD (Arg-Gly-
Asp) sequence for integrin binding,[30–32] and the FN(III12–14) 
domain,[17] which binds a variety of GF families including 
BMP-2.[16,23] The availability of both domains was significantly 
higher on pPEA coatings than on SC-PEA surfaces (p < 0.05). 
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Given that we normalized the graphs to total surface FN 
(Figure 1g and Figure S3f, Supporting Information), we propose 
that the reported differences are not due to the total amount of 
FN adsorbed on the surface (as the densities are similar between 
SC-PEA and pPEA), but instead to the enhanced availability of 
specific binding sites on FN with pPEA.
Next, we used ELISA to quantify the amount of BMP-2 
adsorbed on FN-coated surfaces (on SC-PEA and pPEA 
coatings) from a solution at a concentration of 50 ng mL−1 
BMP-2 (Figure 1i); this is the concentration used in subse-
quent biological experiments. We also assessed the stability 
of the adsorbed BMP-2 on FN-coated pPEA and quantify the 
release from the surface as a function of time. More than 
90% of the adsorbed BMP-2 remains in the surface after 14 d. 
(Figure 1j). In line with the above data on GF binding-site 
availability, more BMP-2 was adsorbed on FN coated on pPEA 
than on SC-PEA (Figure 1i and Figure S4, Supporting Infor-
mation). To assess the spatial distribution of BMP-2 molecules 
on the FN nanonetworks, immunogold staining was performed 
on SC-PEA- and pPEA-treated surfaces coated with different 
concentrations of FN and exposed to 25 ng mL−1 BMP-2 
(Figure 1k). The localization of BMP-2 is indicated by bright 
dots on the AFM images, corresponding to gold nanoparticles 
with a diameter of ≈15 nm conjugated to primary antibodies 
specific for BMP-2 (Figure 1l). Gold nanoparticles indica-
tive of BMP-2 (Figure 1k) interact specifically with individual 
Adv. Sci. 2018, 1800361
Figure 1. Physicochemical characterisation of plasma PEA coatings, FN, and BMP-2 adsorption on pPEA. a) Schematic representation of a custom-made 
plasma polymerization chamber. b) FN structure, showing its three domain types (I, II, III) and functions. Domain III region (III9–10) contains the RGD 
(Arg-Gly-Asp) sequence that facilitates cell adhesion via integrin binding, and region III12–14 binds various GFs, including BMP-2. c) XPS characterization 
of SC-PEA and pPEA. High-resolution C1s and O1s spectra are shown with fitted components in colored dotted lines. d) Chemical structure of PEA, 
with labelled carbon and oxygen atoms corresponding to components in panel (c). AFM phase images of FN adsorbed for 10 min on e) SC-PEA and 
f) pPEA. Thin fibrillar networks were observed on SC-PEA, whereas thick, dense networks were observed on pPEA. g) Surface density of FN adsorbed at 
different concentrations onto SC-PEA and pPEA for 1 h. h) Relative exposure of integrin-binding and GF-binding domains on FN adsorbed on different 
surfaces, measured using ELISA. i) Relative adsorption of BMP-2 on FN-coated surfaces, measured using ELISA. j) Cumulative BMP-2 release from 
surfaces coated with pPEA, FN, and BMP-2 during 2 weeks. k) AFM height images of BMP-2 labelled with gold nanoparticles on SC-PEA and pPEA 
coated with FN. White arrows indicate gold nanoparticles showing BMP-2 distribution. l) Schematic representation of immunogold assay for GF detec-
tion. All data are presented as mean ± SD, n = 3, one-way ANOVA with Tukey’s test for multiple comparisons. *p < 0.05, ns = not statistically significant.
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nanofibers of FN on both SC-PEA and pPEA and confirm the 
specific localization of BMP-2 on FN. (Note that lower concen-
trations of FN and BMP-2 than those used in cell experiments 
were used here to clearly depict this localization.)
2.2. Plasma-Polymerized PEA Coatings Drive Synergistic 
Signaling and hMSC Osteogenesis
To investigate whether pPEA-induced BMP-2 presenta-
tion drives cell adhesion, enhances synergistic integrin/GF 
signalling, and is osteoinductive at low GF concentration, we 
cultured human mesenchymal stem cells (hMSCs) on pPEA 
surfaces first coated with FN and then 50 ng mL−1 BMP-2.
First, cell attachment and spreading after 24 h were signifi-
cantly enhanced on pPEA-coated surfaces with FN compared to 
cells on SC-PEA-coated surfaces with FN (Figure S5, Supporting 
Information), as evidenced by the higher number of attached 
cells, greater degree of spreading, and enhanced focal adhesion 
(FA) formation. This correlated well with the better availability 
of FN(III9–10) domains on pPEA (Figure 1h).
Next, synergistic integrin and GF signalling were evaluated, 
initially by assessing whether BMP receptor 1A (BMPR1A) colo-
calizes with focal adhesions. Vinculin (which stains focal adhe-
sions) immunofluorescence colocalized with BMPR1A immuno-
fluorescence in single cells (Figure 2a), indicating that BMPR1A 
and integrins are in close proximity, which would enable cross-
talk to occur between the adhesion and GF pathways (Figure 2b). 
(The staining of specific integrins is shown in Figure S6 in the 
Supporting Information.) Next, the phosphorylation of small 
mothers against decapentaplegics (SMAD) and focal adhesion 
kinase (FAK) was examined in order to investigate BMP-2-related 
signalling and focal adhesion-related signalling pathways, respec-
tively.[33–35] The expression of phosphorylated SMADs (pSMAD) 
and phosphorylated FAK (pFAK) in hMSCs after 1 h of culture 
on the test versus control surfaces is shown in Figure 2c.
Adv. Sci. 2018, 1800361
Figure 2. hMSC signalling and differentiation. a) Colocalization assay of BMP receptor 1A (BMPR1A, green) and FAs (red). White arrows on the merged 
image show areas of colocalization in yellow. Scale bar = 20 µm. b) A schematic representation showing that synergistic signalling between integrin 
and GF receptors can occur when the integrin-binding (III9–10) and GF-binding (III12–14) domains of FN are in close proximity. c) Western blotting of 
pSMAD 1/5/9 and pFAK, expressed by hMSCs after 1 h in culture on SC-PEA and pPEA, with and without FN and BMP-2. Quantified blots to show 
relative expressions of d) pSMAD and e) pFAK, both normalized using total protein amount, from hMSCs after 1 h in culture on SC-PEA and pPEA, with 
and without FN and BMP-2. hMSCs cultured with soluble BMP-2 and on glass alone were used as controls. Data are presented as mean ± SD, n = 3, 
one-way ANOVA with Tukey’s test for multiple comparisons. *p < 0.05. f) Normalized ALP expression in hMSCs after 12 d in culture on SC-PEA and 
pPEA surfaces, with and without FN and BMP-2, from a fluorescent ALP assay. Data are presented as mean ± SD, n = 3, one-way ANOVA with Tukey’s 
test for multiple comparisons. *p < 0.05. Immunofluorescent labelling of g) OPN and h) OCN in hMSCs cultured on SC-PEA and pPEA, with and 
without FN and BMP-2, for 21 d. Phalloidin stains actin cytoskeleton in green and DAPI stains nuclei in blue. Scale bar = 50 µm.
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SMADs 1, 5, and 9 can be phosphorylated by BMPR1A, leading 
to their nuclear translocation and the activation of RUNX2 (runt-
related transcription factor 2, the osteogenic master transcription 
factor).[33,36] Quantification of pSMAD expression by western 
blotting, normalized by total protein amount (Figure 2d and 
Figure S7, Supporting Information), showed a significant upreg-
ulation of pSMAD on pPEA-coated surfaces with FN and BMP-2 
(pPEA + FN + BMP-2) compared with pPEA without BMP-2 
(pPEA + FN); a similar trend was observed on SC-coated surfaces 
(Figure 2d). In both cases, the presentation of BMP-2 on PEA 
resulted in enhanced SMAD signalling compared to the soluble 
administration of the GF alone (soluble BMP-2, Figure 2d).
We also examined the expression of pFAK in hMSCs, 
which was normalized using total protein amount (Figure 2e 
and Figure S7, Supporting Information). pFAK is involved in 
integrin-related signalling[35,37] and was significantly upregu-
lated (p < 0.05) in hMSCs cultured on surfaces coated with 
pPEA + FN + BMP-2 relative to those cultured without BMP-2 
(pPEA + FN) or with soluble BMP-2 alone (again, a similar 
trend was observed for the control material, SC-PEA). We note 
that in hMSCs cultured with soluble BMP-2, pFAK is induced 
to the same level as it is in cells cultured on pPEA without 
BMP-2, which suggests that increased pFAK expression is focal 
adhesion related and occurs independently of BMP-2. From 
these findings, we propose that enhanced synergistic adhesion 
and BMP-2 signalling on pPEA + FN + BMP-2 occurs as a 
consequence of the simultaneous occupancy of integrins and 
BMP-2 receptors.[35,37]
We next investigated the potential of this synergistic signal-
ling cascade, driven by PEA-induced assembly of FN, for osteo-
genesis. Alkaline phosphatase (ALP) expression was measured 
after 12 d of hMSC culture (Figure 2f). ALP, which plays a role 
in bone mineralisation and is an early marker of osteogenic 
differentiation,[38] was expressed by hMSCs cultured on pPEA + 
FN + BMP-2 at a significantly higher level than it was by cells 
cultured on pPEA + FN without BMP-2 coating. Long-term cul-
ture was also performed for 21 d and two osteogenesis-related 
proteins, osteopontin (OPN) and osteocalcin (OCN), were 
visualized by immunofluorescence (Figure 2g,h and Figure S8, 
Supporting Information). Both OPN and OCN (shown in red) 
were more highly expressed in hMSCs cultured on pPEA + 
FN + BMP-2 than they were by cells cultured on pPEA-FN sur-
faces without BMP-2. Moreover, comparing SC-PEA and pPEA, 
it is clear that when both FN and BMP-2 were present, OPN 
was expressed more distinctly on the pPEA-coated surfaces. 
Von Kossa staining further revealed the presence of mineral-
ized deposits on the surfaces coated with BMP-2 (Figure S9, 
Supporting Information).
As proof of concept that pPEA can be employed as a 
coating for 3D biomaterials, further in vitro analysis was 
performed on 3D polycaprolactone (PCL) scaffolds (cylinders 
of 5 mm diameter, 800 µm high). The scaffolds were fab-
ricated by 3D printing (to generate filaments of 200 µm in 
diameter, with 500 µm separation, layered at 90° to the last 
layer, see Figure S10a in the Supporting Information). Once 
fabricated, the scaffolds were coated with pPEA for 30 min 
before adsorbing FN to generate a fibrillar network (inset, 
Figure S10a, Supporting Information). FN adsorption was con-
firmed by ELISA (Figure S10b, Supporting Information). The 
expression of BMPR-2, RUNX2, and osterix (OSX) was then 
quantified by quantitative polymerase chain reaction (qPCR) 
(Table 1, Supporting Information). qPCR results showed that 
by day 7 in culture, OSX expression (but not that of BMPR-2 
and RUNX2 at this time point) was significantly increased in 
hMSCs cultured on PCL + pPEA + FN + BMP-2, compared 
to cells cultured on PCL + pPEA or on PCL + pPEA + FN 
(Figure S10c, Supporting Information). It is likely that BMPR-2 
and RUNX2 upregulation had occurred at an earlier time point 
(previous reports have shown that BMPR-2 levels are highest 
at day 3, and RUNX2 levels highest at day 5 of culture, while 
OSX expression occurs later at days 7–11[39]). With respect to 
RUNX2, a significant increase in its phosphorylation was seen 
in PCL + pPEA + FN + BMP-2 as early as day 5 in culture, rela-
tive to other controls (PCL, PLC + pPEA, PCL + pPEA + FN) 
(Figure S10d, Supporting Information). After longer-term cul-
ture (21 d), mature bone nodules could be observed by Alizarin 
red staining on the scaffolds coated with PCL + pPEA + FN + 
BMP-2 (Figure S10e, Supporting Information).
2.3. Plasma-Polymerized PEA Coatings Drive Regeneration 
in a Murine Nonhealing Radial Bone Defect Model
To investigate the translational potential of the osteogenic pPEA 
coatings, we used an adult mouse model of a critical-sized, 
nonhealing radial bone defect.[17] This bone repair model has 
significant advantages: i) the 2.5 mm defect does not sponta-
neously heal, providing a rigorous critical-sized model, ii) it 
allows for simple in vivo imaging approaches (e.g., microcom-
puted tomography, µCT), and iii) the ulna provides sufficient 
stabilization of the defect and no fixation plates/hardware are 
required. This simplifies the surgical procedure and reduces 
the risk of infection, a major advantage over the rat calvaria and 
segmental femur defect models.[21]
Polyimide tube implants of 4 mm were used in this model 
as they form a biocompatible but nonbioactive scaffold that 
fits well over the defect (Figure S11, Supporting Information). 
These were coated with degradable PCL by solvent casting, 
creating a layer of an FDA-approved biomaterial within the 
tube. This was followed by polymerization of a very thin layer 
of pPEA (estimated at <100 nm) to cover the underlying PCL 
polymer. Then, FN or FN + BMP-2 was adsorbed on the cylin-
drical polymer surface. BMP-2 was used at low concentration, 
i.e., ≈15 ng of BMP-2 on the wall of the coated tubes (surface 
density of 100 ± 8 ng cm−2, as measured using ELISA).[17] This 
BMP-2 concentration is at least 100% lower than that used in 
advanced materials systems previously tested in murine models 
that are based on integrin-specific polyethylene glycol hydrogels 
loaded with BMP-2.[21] Note that even if humans and rodents do 
not metabolize biologics at the same rate, the amount of 
BMP-2 used was ≈300 fold lower than that of the clinical gold 
standard.[14,17] Implant tubes without BMP-2 coated only with 
the PCL layer or with PCL + pPEA were used as negative con-
trols. FN and BMP-2 adsorbed on solvent-casted PEA were used 
as positive controls based on previous data.[17]
Bone formation was evaluated by X-ray (Figure 3a) and by 
3D µCT reconstructions, which displayed the total length of 
the radius scanned (Figure 3b). The 3D µCT images showed 
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increased bone growth along the defect in the presence of 
BMP-2, to the extent where the bone gap is fully bridged 
(Figure 3b). These results show that higher levels of bone 
regeneration occurred in the presence of BMP-2, even when 
it was only applied to the walls of the implant tube, as per-
formed here. Most importantly, similar levels of bone regen-
eration are seen on samples coated with solvent-casted PEA 
(positive control) and on the test material pPEA, which indi-
cates enhanced in vivo effects of pPEA, even with the use of 
low doses of BMP-2 (Figure 3b). Further, limb function was 
restored in all treated mice. The quantification of bone for-
mation from µCT images shows enhanced bone surface den-
sity in the presence of low-dose BMP-2 (both on PEA and 
pPEA) compared to conditions where no BMP-2 was present 
in the implant (Figure 3c), albeit the same bone volume was 
found in all other conditions tested (Figure 3c). The discrep-
ancy between bone volume and bone surface density between 
groups is a reflection of how bone is organized within the 
defect, allowing or not full bridging. A way to measure the 
architecture of new bone is by analyzing the 3D information 
provided by µCT and quantify the total surface of bone formed. 
This is particularly relevant for areas of the implant functional-
ized with BMP2, as a new layer of bone grows in contact with 
them. These results suggest the different organizations of 
bone, leading to the full bridging of defects in the pPEA + FN 
+ BMP-2 condition (Figure 3b).
The histological sections in the area of the defect support 
the findings obtained from the µCT images. Implant tubes 
(solvent-casted PEA and pPEA) coated with FN and BMP-2 
induced higher levels of new bone formation, relative to controls 
(Figure 3d,e). Both proximal and distal bone extended into the 
implant, and structures that resemble the bone marrow were 
observed along the entire defect (Figure 3d,e). However, a larger 
gap between proximal and distal bone was observed in the 
absence of BMP-2 (Figure 3f,g), with less bone healing observed 
for PCL-only control implants (Figure 3h). Moreover, fibroblast-
like structures were observed filling the gap of the defect in PCL-
only control implants, with cartilage tissue present (red staining 
in Figure 3h), indicating the differentiation of cells toward the 
chondrogenic lineage.
Taken together, the in vitro and in vivo data indicate 
that the synergistic integrin/BMP-2 receptor osteoinduc-
tive response is generated by pPEA-coated scaffolds. From 
these findings, we propose this polymerization approach as 
a potential method for coating material implants in 2D and 
3D scaffolds.
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Figure 3. Bone regeneration in a murine model of a critical-sized radial bone defect with low doses of BMP-2. a) X-ray images at 0, 4, and 8 weeks 
after surgery. b) 3D reconstructions from the µCT images showing the radius in the area of the defect, 8 weeks after introduction of the PCL-pPEA 
implant (with or without FN and BMP-2). c) Quantification of the volume and specific surface of new bone. Data are presented as mean ± SD, 
minimum n = 3. Two-tailed t-test was used to analyze data. *p < 0.1. d–h) Hematoxylin-Safranin O-fast green staining of histological sections in the 
area of the defect. The tissue is organized in structures resembling bone marrow (rounded white structures in panels (d) and (e)) versus fibroblast-
like morphology (extended and aligned) in the center of the defect in panels (f)–(h). Arrow points to red staining that indicates cartilage formation 
in panel (h).
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2.4. Veterinary Case Study: pPEA Supports Healing  
of a Nonunion Humeral Fracture in a Dog
To demonstrate the translatable potential of the pPEA system, 
we performed a first trial of this approach in a veterinary 
case study. A 2-year-old female Münsterländer dog (Figure 4a 
and Figure S12 and Video S1, Supporting Information) was 
presented to the Small Animal Hospital, University of Glasgow, 
in July 2016 for the management of a comminuted fracture 
of the diaphysis of the right humerus, sustained when she 
was hit by a car (Figure 4b). The fracture was stabilized sur-
gically using a standard open reduction and internal fixation 
technique (Figure 4c). The dog made a slow early recovery, 
retaining a significant degree of lameness and developed a 
discharging sinus on the medial aspect of the distal humerus 
around 2 months postoperatively, indicative of an infection at 
the fracture site. This was confirmed when Staphylococcus spp. 
was cultured from this sinus. The infection was treated with 
antibiotics (potentiated amoxicillin, 500 mg by mouth three 
times daily) for 6 weeks based on the sensitivity profile. Despite 
this, the dog remained persistently lame. Five months after 
surgery, there was no convincing evidence of fracture healing. 
Radiographically, areas of osteolysis and implant loosening 
indicated the presence of osteomyelitis and delayed union 
(Figure 4d).
We removed the implants on the basis that a bacterial biofilm 
was likely covering them and perpetuating the infection. 
The fracture was restabilized with an external skeletal fixator 
(Figure 4e) and antibiotic treatment continued (potentiated 
amoxicillin, 500 mg by mouth twice daily) for a further 2 weeks, 
as Staphylococcus spp. cultured directly from the metal implants 
showed the same sensitivity profile as previously shown.
Radiographs taken 6 weeks after revision surgery showed 
no evidence of fracture healing and significant osteolysis 
(Figure 4f). We were concerned that this fracture was devel-
oping an atrophic nonunion, and radiographs taken 10 weeks 
postrevision (8 months following the original injury) were 
consistent with this (Figure 4g). Because of the poor prognosis, 
we considered limb amputation but instead elected to revise 
the fracture fixation once more using allograft microparticles 
coated with pPEA on which FN and BMP-2 were adsorbed at 
50 µg mL−1. This concentration is 30-fold lower than that used 
in clinical standards (BMP-2 loaded in a collagen sponge at a 
concentration of 1.5 mg mL−1).[14] We note that while this is a 
higher concentration than that used in our in vivo mouse bone 
defect model, it is still only 10% of the dose (0.5 mg mL−1) 
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Figure 4. Humeral fracture healing in a dog treated with bone chips coated with pPEA, FN, and BMP-2. a) A schematic representation of a 2-year-old 
female Münsterländer dog, showing a comminuted fracture of the diaphysis of her right humerus, sustained when she was hit by a car. b) Radiograph 
of the comminuted fracture of the diaphysis of the right humerus. c) Radiograph showing the surgical stabilisation of the fracture using standard open 
reduction and internal fixation technique. d) Five months after c), osteolysis at the fracture site was evident, consistent with osteomyelitis and delayed 
union. e) Restabilization of the fracture using an external skeletal fixator. f) Six weeks after (e), there was no evidence of fracture healing. g) Radiograph 
showing fracture nonunion, 8 months after the injury. h) Prior to surgery, decellularized bone chips were coated with pPEA to form pPEA-chips, which 
were subsequently coated with FN and BMP-2. i) Bone marrow was harvested from the humeral head on the left side and mixed with 5 cc of coated 
pPEA-chips. j) Bone plates and screws were used to stabilize the fracture, and the combined graft materials were placed within the fracture gap. 
k) Postoperative radiograph shows the fracture gap filled with graft. l) Evidence of fracture union 7 weeks after surgery performed in panels (g) to (j).
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typically used in complex fractures in dogs in veterinary 
applications.[40]
Decellularized bone chips (2–4 mm) were coated with pPEA 
using plasma polymerization to form pPEA-chips and sub-
sequently coated with FN and BMP-2 (Figure 4h). A standard 
medial approach was made to the humerus. Approximately 
1 cm of the nonhealing ends of the fracture was excised, along 
with all soft issue within the fracture gap. Bone marrow was 
harvested from the humeral head on the left side and mixed 
with 5 cc of pPEA-chips (Figure 4i). The fracture site was thor-
oughly debrided and then stabilized using two bone plates and 
screws and the combined graft materials were placed within 
the fracture gap (an ≈2 cm defect) (Figure 4j); soft tissues 
were closed as per routine protocol. Postoperative radiographs 
showed the fracture gap filled with graft and the appropriate 
placement of the implant (Figure 4k). The dog made a good 
recovery from the procedure.
There was a moderate degree of postoperative swelling of 
the affected limb, which resolved within a week, but no other 
adverse effects were observed. The tissue removed from the 
fracture site was submitted for bacterial culture, which showed 
the persistence of a Staphylococcus infection. Antibiotics were 
prescribed (cephalexin 300 mg by mouth twice daily) and 
continued for 4 months postoperatively. The dog’s use of the 
affected limb steadily improved, and radiographs taken 7 weeks 
after surgery were consistent with fracture union (Figure 4l). By 
6 months postoperatively, the dog had resumed normal exercise, 
and there was no clinical evidence of recurring infection.
3. Discussion
Notwithstanding significant off-target effects, BMPs have been 
used in patients for the management of nonunion fractures 
where traditional approaches have failed.[14] Here, we present a 
simple and facile technology that allows materials with complex 
geometries to be coated with ultralow and thus safer levels of 
BMP-2 for use in bone regeneration-promoting therapies to 
treat critical-sized, nonunion bone defects. Plasma polymeriza-
tion presents a solvent-free coating method that can be used for 
a variety of 3D applications, such as scaffolds and grafts.
This new approach produces thin PEA coatings (layers of 
30–200 nm are possible) which are strongly attached to the 
underlying substrate (≈7.10 MPa – Figure S1, Supporting 
Information) that can assemble FN in the form of biomimetic 
nanonetworks (Figure 1f), rather than as a globular structure. 
This unfolding of the FN molecule via nanonetwork formation 
exposes sites responsible for FN function, such as integrin-
binding (III9–10) and GF-binding (III12–14) regions.
[17,23,30,31]
In in vitro assays, synergistic signalling was observed in 
hMSCs cultured on surfaces coated with pPEA + FN + BMP-2, 
together with the upregulation of pSMADs (Figure 2c,d), indi-
cating the onset of canonical BMP-2 signalling mediated by 
BMP receptors, as shown previously.[17] Increased pFAK with 
BMP-2 stimulation from the surface but not in soluble form 
indicates integrin ligation.[35] Previous research has shown that 
intact integrin function is crucial for BMP-2 activity and that 
inhibition of FAK activation blocks SMAD signalling activa-
tion by BMP-2.[37] The upregulation of pFAK on BMP-2-coated 
surfaces is shown in Figure 2c,e, signifying that the combined 
effects of pSMAD and pFAK signalling could be a consequence 
of the potency of BMP-2 in enhancing downstream osteogenic 
activities. Previous evidence has demonstrated that crosstalk 
occurs between GF receptors and integrins, which plays a crucial 
role in regulating mechanotransduction in the extracellular 
matrix.[17,37,41–43] The colocalization of BMP-2 receptors with var-
ious types of integrins has been demonstrated previously,[17,37,39] 
and this colocalization is confirmed in our study (Figure 2a).
We show that pPEA + FN + BMP-2 promotes bone regen-
eration in a critical-sized defect in the mouse radius. The effect 
is similar (full bridging of the defect and histological evidence 
of new bone growth) to the use of bulk PEA deposited using 
solvent-casting.[17] We found that pPEA was not effective in pro-
moting regeneration if only coated with FN, which reveals the 
importance of the minimal amount of BMP-2 used (≈15 ng) 
(Figure 3b). It is noteworthy that the use of pPEA and pPEA + FN 
in the mouse model came closer to bridging the bone defect 
than did the use of PCL alone (Figure 3b), indicating that 
passive adsorption of adhesion proteins and GFs from the 
mouse host might also occur onto the scaffold. Nevertheless, 
our data indicate that engineering adhesion in this way can only 
enhance osteogenesis to a certain extent. To regenerate bone 
and repair large defects in a reasonable time, synergistic signal-
ling between integrins and GF receptors is required in vivo.
Further, we translate the technology to demonstrate the appli-
cation and efficacy of this approach in promoting bone regen-
eration in a veterinary case of an infected nonunion fracture. 
In a previously reported recent case study, dogs suffering from 
nonunion long-bone fractures were treated with a compression-
resistant matrix soaked in a solution of 0.5 mg mL−1 BMP-2.[40] 
Here, we report the successful repair of a nonunion fracture in 
a dog using decellularized bone chips treated with a novel pPEA + 
FN + BMP-2 coating using only 10% of the BMP dose previ-
ously reported.[40] The bone chips themselves facilitated healing 
of the defect only through osteoconduction, as this kind of graft 
material has no inherent osteoinductive capacity.[44] Fracture non-
union in our hospital is uncommon, and these cases are highly 
variable, so it was not possible to treat a control animal with sim-
ilar injury, infection, and compromised bone healing. Our con-
clusions should therefore not be overstated; however, based on 
clinical experience, we feel that the rapid and robust bone healing 
observed would not have occurred had the surgery been supple-
mented using bone chips alone. We note that the treatment of 
infected critical-sized defects, to which we demonstrate a regener-
ative approach, is a major clinical challenge in orthopedic surgery.
Other strategies to present GFs from a material surface, 
including protein engineering techniques, the use of peptides 
that bind heparin and GFs,[45] and the use of layer-by-layer tech-
nologies,[41] are reported to be more effective than the soluble 
administration of GFs.[46] However, these approaches do not 
exploit the synergy between integrin and GF receptors to 
enhance accelerated regeneration.[47]
4. Conclusion
To conclude, we show here that the delivery of BMP-2 at 
ultralow doses in synergy with integrin-binding regions of FN 
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can overcome the current obstacles facing orthopedic treat-
ments, such as the regeneration of infected bone. This system 
has the potential to be developed into a safe, efficient, and 
cost-effective therapeutic approach for delivering BMP-2 at low 
doses to stimulate bone regeneration and demonstrates the clin-
ical potential of new biomaterials. The study represents a first 
translation of a polymer/biological interface that targets repro-
ducible molecular control of cell phenotype through multiple 
cell receptor targeting. This strategy can be potentially used in 
other applications where the use of growth factors is important 
to achieve cellular effects, such as cardiovascular tissue engi-
neering, regeneration of osteochondral defects, and nerve repair.
5. Experimental Section
Plasma Polymerization: Circular 12 mm diameter microscopy 
cover glasses were sonicated for 25 min in ethanol and treated in air 
plasma for 5 min before being exposed to monomer plasma. Plasma 
polymerization of the ethyl acrylate monomer (E9706, Sigma-Aldrich) 
onto the substrates was carried out in a custom-made capacitively 
coupled plasma installation for low-pressure plasma in a 15-L T-shaped 
reactor made of borosilicate and stainless steel end plates sealed with 
Viton O-rings. Vacuum was produced by a rotary pump or a scroll pump 
(both BOC Edwards), with operating experiment pressures for the 
monomer plasma from 0.09 to 0.45 mbar. The plasma was initiated via 
two capacitively coupled copper band ring electrodes situated outside 
of the reactor chamber and connected to a radio frequency power 
supply (Coaxial Power System Ltd.) that works at 13.56 MHz up to 
300 W. The monomer pressure was controlled via speedivalves (BOC 
Edwards) and monitored with a pirani gauge (Kurt J. Lesker). Control 
samples were prepared by spin-coating PEA dissolved in toluene at 
4% wt/wt. PEA sheets were prepared by radical polymerization of ethyl 
acrylate solution using 1% benzoin as photoinitiator. A 100 µL droplet 
of the polymer solution was placed on the glass coverslip, and spin 
coating was operated at a speed of 3000 rpm and an acceleration of 
3000 rpm s−1 for 30 s. The PEA-coated coverslips were then subjected to 
solvent extraction under vacuum at 60 °C for at least 2 h to ensure that 
no traces of solvent remained on the surface.
XPS: X-ray photoelectron spectra were obtained at the National 
EPSRC XPS Users’ Service (NEXUS) at Newcastle University, an EPSRC 
Mid-Range Facility. XPS was performed using a K-Alpha apparatus 
(Thermo Scientific), with a microfocused monochromatic Al Kα source 
(X-ray energy = 1486.6 eV) at a voltage of 12 kV, current of 3 mA, power 
of 36 W, and spot size of 400 µm × 800 µm. Spectra analysis and curve 
fitting were performed using CasaXPS software version 2.3.16.
AFM: Human FN (1918-FN, R&D Systems) was prepared at 
20 µg mL−1 in Dulbecco’s phosphate-buffered saline (DPBS) and a 
200 µL droplet was placed on the surface of glass coverslips treated with 
either spin-coated PEA (SC-PEA) or pPEA. The protein was allowed to 
adsorb for 10 min and the remaining liquid was thereafter removed 
from the surface. The surface was then washed twice with DPBS and 
once with Milli-Q water and dried under a stream of nitrogen before 
AFM imaging. A JPK Nanowizard 4 (JPK Instruments) apparatus was 
used for imaging in tapping mode using antimony-doped Si cantilevers 
with a nominal resonant frequency of 75 kHz (MPP-21 220, Bruker). The 
phase signal was set to 0 at a frequency 5–10% lower than the resonant 
frequency. Height and phase images were acquired from each scan. The 
JPK Data Processing software version 5 was used for image analysis.
Protein Adsorption Assays: ELISA was performed to assess the 
exposure of specific domains on the FN molecule. After substrates had 
been coated with 20 µg mL−1 FN in DPBS for 1 h, they were blocked 
for 30 min with 1% bovine serum albumin (BSA, A7979, Sigma-Aldrich) 
in DPBS. Next, antibodies for the FN(III9–10) domain (HFN7.1, mouse 
monoclonal, 1:330, Developmental Studies Hybridoma) or FN(III12–14) 
domain (P5F3, sc-18 827, mouse monoclonal, 1:30, Santa Cruz 
Biotechnology) were added onto the surfaces and incubated for 1 h. The 
surfaces were thereafter washed 3 × 5 min with 0.05% Tween 20 in DPBS 
(PBST). Then, a horseradish peroxidase (HRP)-conjugated antimouse 
antibody (626 520, 1:200, ThermoFisher) was added onto the surface 
and incubated for 1 h in the dark, following by washing for 3 × 5 min 
with PBST. A substrate solution (DY999, R&D Systems) was then 
added onto the surfaces and the samples were incubated in the dark 
for 20 min, followed by the addition of a stop solution (DY994, R&D 
Systems). The absorbance of the colored solution was read at 450 and 
540 nm and the data were used to determine the relative exposure of the 
FN domains. All procedures were performed at room temperature.
ELISA was also performed to quantify BMP-2 adsorption. After FN 
was coated at 20 µg mL−1 for 1 h, the surfaces were blocked with 1% 
BSA in DPBS for 30 min, followed by adsorption of BMP-2 (355-BM, 
R&D Systems) in DPBS for 1 h. The surfaces were washed and blocked 
again with 1% BSA for 30 min. Next, primary antibodies against BMP-2 
(ab14933, rabbit polyclonal, 1:2000, Abcam) were added onto the 
surfaces and incubated for 1 h. After washing for 3 × 5 min with PBST, a 
biotinylated antirabbit antibody (BA-1100, 1:10 000, Vector Laboratories) 
was added onto the surfaces and incubated for 1 h. The samples were 
then washed again for 3 × 5 min with PBST, and a streptavidin-HRP 
solution (DY998, R&D Systems) was added and incubated for 20 min. 
After a final 3 × 5 min wash with PBST, a substrate solution was added 
onto the surfaces and the samples were incubated in the dark for 
20 min, followed by the addition of a stop solution. The absorbance of 
the colored solution was read at 450 and 540 nm and the data were 
used to determine the relative adsorption of BMP-2. All procedures were 
performed at room temperature.
Quantification of BMP-2 Release from pPEA-Coated Surfaces: To 
determine the degree of BMP-2 release from pPEA-FN-coated surfaces, 
BMP-2-loaded samples were incubated at 37 °C for 1 h. At 14 different 
time points (2 h and 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, and 14 d), 
supernatant was collected and samples were replenished with fresh 
buffer. The amount of BMP-2 in the supernatant was measured using 
sandwich ELISA (DY355, R&D Systems) following the manufacturer’s 
instructions. Briefly, ELISA plates were coated with the capture 
antibody and then blocked with BSA for 1 h. After appropriately diluted 
supernatants were added, bound BMP-2 was detected with biotinylated 
antihuman BMP-2. Streptavidin-conjugated HRP was then added to 
the plates. Enzyme substrate (tetramethylbenzidine and peroxide) 
was treated for 20 min, and the reaction was stopped by adding an 
acidic solution. Absorbance was measured at 450 nm with wavelength 
correction at 570 nm. The standard curve was calculated using a 
four-parameter logistic (4-PL) curve fit. The amount of BMP-2 was 
calculated from a standard curve based on known concentrations of 
BMP-2. Experiments were performed with three replicates of each time 
point.
Immunogold Characterization of FN-GF Interactions: For immunogold 
characterization using AFM, immunogold staining was performed on 
SC-PEA- and pPEA-modified glass surfaces coated with 3 µg mL−1 FN 
and subsequently with 25 ng mL−1 BMP-2. The samples were washed 
three times with DPBS and fixed with 4% formaldehyde. They were then 
incubated with primary antibodies against human BMP-2 (MAB3551, 
mouse monoclonal, 1:50, R&D Systems) for 1 h at room temperature. 
After washing the samples three times with 0.5% Tween-20 in DPBS 
(wash buffer), an antimouse immunogold reagent conjugated to 15 nm 
gold nanoparticles (815.022, 1:50, Aurion) was added to the samples 
for 1 h at room temperature. The samples were then rinsed with wash 
buffer and fixed again with 4% formaldehyde and imaged using AFM.
Cell Culture: hMSCs (PromoCell) were used for the experiments. Cells 
were cultured in Dulbecco’s Modified Eagle’s Medium (D5671, Sigma-
Aldrich) with 10% fetal bovine serum (10 500-064, ThermoFisher), 0.4% 
penicillin/streptavidin (P0781, Sigma-Aldrich), 1 × nonessential amino 
acids (11 140-035, ThermoFisher), and an antibiotic mix consisting 
of 1 × 10−3 M sodium pyruvate (S8638, Sigma-Aldrich), 1 × 10−3 M 
L-glutamate (G7513, Sigma-Aldrich), and 0.5% Fungizone (15 290-018, 
ThermoFisher). Cells were incubated in a 5% humidified CO2 
atmosphere at 37°C. Cells were used at passages 2–3 and experiments 
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were performed in triplicates. For all experiments, cells were cultured 
initially without serum for 3 h.
Colocalization Studies: Cells were washed with DPBS and fixed 
with 4% formaldehyde solution at 4 °C for 15 min. Cells were then 
permeabilized with a solution of 0.1% Triton X-100 in DPBS at 4 °C for 
10 min. A 1% BSA solution was added and the cells were incubated 
at room temperature for 30 min to block nonspecific binding. After 
blocking, primary antibodies (antivinculin, V9131, mouse monoclonal, 
1:400, Sigma-Aldrich; anti-BMPR1A, PA5-11 856, rabbit polyclonal, 
1:50, ThermoFisher) were added to the cells and incubated at 37 °C 
for 1 h. Cells were then washed with 0.5% Tween-20 in PBS (PBST) for 
3 × 5 min. Thereafter, AlexaFluor 488 donkey α-mouse (A21202, 1:200, 
ThermoFisher) and Cy3-conjugated goat α-rabbit (711-165-152, 1:100, 
Jackson ImmunoResearch) were added to the cells and incubated at 
37 °C for 1 h, followed by PBST washing for 3 × 5 min. The nuclei of 
the cells were stained using VectaShield-4′,6-diamidino-2-phenylindole 
(DAPI) (H-1200, Vector Laboratories), while samples were mounted on 
glass slides for fluorescence microscopy.
Western Blot: Cell lysates were harvested after culturing on various 
surfaces for 1 h, using radioimmunoprecipitation (RIPA) buffer 
supplemented with protease inhibitors (S8830, Sigma-Aldrich) and 
phosphatase inhibitors (78 427, ThermoFisher). Western blotting 
was performed using the same amount of protein in each sample in 
denaturing conditions for pSMAD 1/5/9 (12656T, rabbit monoclonal, 
1:1000, Cell Signaling) and pFAK (05-1140, mouse monoclonal, 1:500, 
EMD Millipore). After membranes were washed in Tris-buffered saline 
with Tween 20 for 6 × 5 min, antirabbit (7074, 1:2000, Cell Signaling) 
and antimouse (NA931VS, 1:10 000, Abcam) secondary antibodies were 
added, and a chemiluminescent HRP substrate for immunodetection 
(Millipore, WBKLS0500) was used before X-ray detection. Protein 
expression was quantified using ImageJ and normalized with total 
protein amount measured by BCA (23 225, ThermoFisher).
ALP Assay: Cells grown on coverslips were rinsed twice with DPBS 
and harvested prior to ALP assay. Each coverslip with attached cells was 
broken into pieces and transferred to a 1.5 mL Eppendorf tube. Then, 
500 µL of ice-cold Tris-HCl was added to each tube. The sample was 
sonicated twice for 10 s each at 5 W and centrifuged at 10 000 × g for 
5 min. The supernatant was transferred to a new tube and the protein 
concentration of each sample was measured by BCA assay (23 225, 
ThermoFisher). Then, a sample volume corresponding to 25 µg of 
protein (adjusted to 25 µL with DPBS) was added to each well of a black 
96 well plate, and 100 µL of a fluorescent 4-methylumbellifeyl phosphate 
disodium salt (MUP, M8168, Sigma-Aldrich) substrate solution, made 
by mixing 500 µL of 1 M NaHCO3, 2 mL of 50 × 10−3 M diethanolamine, 
7.5 mL of deionized water, and 34 µL of 25 mg mL−1 MUP stock, was 
added to each well. After incubating at 37 °C for 1 h in the dark, the 
fluorescence of the plate was read at an excitation wavelength of 360 nm 
and an emission wavelength of 465 nm. ALP standards were prepared 
using serial dilutions of a 10 mU µL−1 ALP solution (P6774, Sigma-
Aldrich) to obtain a calibration curve.
Immunofluorescence of Osteogenesis-Related Markers: Cells were 
washed with DPBS and fixed with 4% formaldehyde solution at 4 °C 
for 15 min. Cells were then permeabilized with a solution of 0.1% 
Triton X-100 in DPBS at 4 °C for 10 min. Blocking was performed 
using 1% BSA at room temperature for 30 min. Primary antibodies 
(anti-OPN, sc-21 742, mouse monoclonal, 1:100, Santa-Cruz 
Biotechnology; anti-OCN, sc-73 464, mouse monoclonal, 1:100, Santa-
Cruz Biotechnology) were added to the cells and incubated at 37 °C 
for 1 h. Cells were then washed with PBST for 3 × 5 min. Thereafter, 
AlexaFluor 488 donkey α-mouse (A21202, 1:200, ThermoFisher) 
and Cy3-conjugated goat α-rabbit (711-165-152, 1:100, Jackson 
ImmunoResearch) were added to the cells and incubated at 37 °C for 
1 h in the dark, followed by PBST washing for 3 × 5 min. The nuclei 
of the cells were stained using VectaShield-DAPI, while samples were 
mounted on glass slides for fluorescence microscopy.
Implant Preparation for In Vivo Study of Nonunion Critical-Sized Bone 
Defect: Thin, porous polyimide sleeves (Microlumen) were coated 
by solvent casting of a PCL solution, creating a polymer layer on the 
walls of the tube, followed by the deposition of a thin layer (<1 µm) 
of pPEA to cover the underlying PCL polymer. Then, FN or FN + BMP-2 
was adsorbed on the cylindrical polymer surface. Implant tubes 
without BMP-2 and tubes coated with the sole polymer layer of PCL 
or PCL + pPEA were used as controls. Implant tubes covered with 
solvent-casted PEA coated with FN and BMP-2 were used as a positive 
control, this condition being the one that showed a higher potential in 
promoting bone regeneration in the preliminary experiment.[17] At least 
three replicates per group were used in the experiment. It was important 
to note that implant tubes coated was used with the polymer of interest 
instead of 3D scaffolds, due to the size limitations of the small animal 
model.
Nonhealing Bone Defect Model in Mice: All in vivo experiments were 
conducted under the Animals (Scientific Procedures) ACT 1986 (ASPel 
project license n° 70/8638). Male B6-129 mice (8–10 weeks old, Charles 
River) were used for these studies. Mice were fully anesthetized using 
isoflurane gas as an anesthetic agent. To create bone defects, the 
midsection of the radius and ulna in the right front paw of the mouse 
was exposed. A custom-built double-blade bone cutter was used to 
precisely generate a 2.5 mm segmental defect on the radius without 
disturbing the ulna. The implant tube (4.0-mm long) was fitted over 
the ends of the defect. After repositioning the muscle and skin, the 
wound was closed and the mouse was completely ambulatory following 
recovery. Figure S11 in the Supporting Information shows a scheme of 
the segmental bone model used.
Analysis of New Bone Formation: Bone growth in the area of the defect 
was evaluated 8 weeks after implantation. Bone samples were explanted 
and analyzed by X-ray (SARRP, Perkin Elmer 0820 detector panel) and 
µCT scanning (Bruker Skyscan Micro X-ray CT). Then, tissue samples 
were decalcified and embedded in paraffin and histological sections were 
stained with hematoxylin-Safranin O-fast green. 3D reconstructions of 
4 mm length of the bone radio in the area of the defect were obtained by 
contouring 2D slices from the µCT scans. Quantification of the volume 
and specific surface of new bone within the defect was performed 
using the free CTAn software from Bruker. In order to ensure that only 
new bone formation was measured, the volume of interest (VOI) was 
selected to evaluate a central 2.0 mm length in the area of the defect. 
The 3D volume measurement was based on the marching cubes volume 
model of the binarized objects within the VOI. The specific surface 
was evaluated as the ratio of solid surface to volume measured in 3D 
within the VOI. This was a basic parameter to assess the thickness 
and complexity of structures, and thus was useful to characterize the 
complex porous structure of the bone.
Preparation of Bone Chips for Implantation: Commercially available 
dog bone chips (Veterinary Instrumentation Ltd.) were coated with 
pPEA. A total of 5 cc of cancellous canine chips, with a chip size 
of 2–4 mm, were spread on a glass petri dish and placed in the 
aforementioned custom-made plasma chamber. The chips were coated 
with a plasma power of 100 W for 30 min. Monomer pressure during 
plasma was 1.8 to 2.4 × 10−1 mbar. After plasma, the chips were 
sterilized under UV light for 15 min and then coated with adsorbed 
FN and BMP-2. First, 10 mL of FN in DPBS at 20 µg mL−1 was used 
to coat the chips, using vacuum to ensure that the liquid reached the 
entire surface of the chips. After 1 h of adsorption, the remaining liquid 
was removed using a pipette. Then, 6 mL of BMP-2 at 50 µg mL−1 was 
added to the chips. Vacuum was once again used to ensure full surface 
coating. The chips were moved into the operating theater and after 2 h 
of GF adsorption, the chips were spread on a surgery gauze to soak 
all the remaining liquid and thereafter directly used by the veterinary 
surgeon.
Clinical Veterinary Case— Details of Surgery and Postoperative Care: The 
local ethics committee was consulted regarding this novel procedure, 
and the informed consent of the dog’s owner was obtained prior to the 
procedure. The Münsterländer dog (2-year-old female, neutered, body 
weight 21 kg) was anesthetized using a standard protocol: premedication 
with methadone (6 mg IM) and medetomidine (100 µg IM), induction 
with propofol (30 mg IV), and maintenance with isoflurane in oxygen. The 
entire right humerus and proximal third of the left humerus were clipped 
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and aseptically prepared for surgery. For analgesia, a brachial plexus nerve 
block was performed preoperatively using 20 mg of levobupivacaine, 
and methadone (6 mg IV) was given once during surgery. A standard 
surgical approach was made to the fractured humerus, on its medial 
aspect. Approximately 1 cm of the nonhealing ends of the bone were 
excised, along with all soft tissue within the fracture gap. The fracture was 
stabilized using a 3.5 mm locking compression plate (Synthes) placed 
medially and a 2.7-mm locking compression plate (Synthes) placed 
cranio-medially. A standard surgical approach was made over the greater 
trochanter of the left humerus and a hole was drilled in the lateral cortex 
using a 4.5 mm drill bit. A curette was used to harvest cancellous bone 
from the humeral head, which was then mixed with 5 cc of pPEA-chips 
(decellularized bone chips coated with pPEA using plasma polymerization 
and subsequently with FN and BMP-2, as previously described). The 
combined graft materials were placed within the fracture gap using 
Debakey forceps. The muscle layer was closed using polydioxanone in a 
simple continuous pattern and skin was closed using poliglecaprone 25 
in an intradermal pattern. Surgical time was 4 h and 5 min and recovery 
from anesthesia was rapid and smooth. For postoperative analgesia, 
methadone (6 mg IM) was given every 4 h for the first day postoperatively 
and meloxicam (2 mg PO SID) was prescribed for 2 weeks. Seven weeks 
after surgery, the dog was sedated with medetomidine (200 µg IV) and 
butorphanol (2 mg IV) for radiography of the humerus, and recovered 
well from this procedure. The dog attended twice weekly physiotherapy 
sessions for 5 months postoperatively, and daily physiotherapy exercises 
were encouraged at home. For the first 7 weeks, physiotherapy included 
the application of pulsed electromagnetic field therapy to the fracture site 
(50 Hz, constant pulse, for 30 min twice daily, Biomag 2 Therapy Unit, 
Westville Therapy). The dog’s exercise was restricted to short controlled 
lead walks for around 3 months after surgery; it was then progressively 
increased as limb function improved.
Statistical Analysis: Experiments were performed in triplicates 
(n = 3) and data were expressed as mean ± SD. Statistical analysis was 
performed by one-way analysis of variance (ANOVA) with Tukey’s test 
for multiple comparisons using OriginPro 8. Statistical significance 
was defined as p < 0.05. For in vivo experiments, data were presented 
as mean ± SD, minimum n = 3. Two-tailed t-test was used to analyze 
data, p < 0.1.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author. Data and materials availability: All the original data 
related to this article are within the depository of the University of 
Glasgow with doi:10.5525/gla.researchdata.700. Additional data related 
to this paper may be requested from the authors.
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